GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Onesource Specialty Pharma Ltd

OneSource Specialty Pharma Partners Formycon for Biosimilar Manufacturing

JV / MOU ▲ Positive Development LOW RISK
📅 Filed on BSE: 14 Jul 2026, 10:00 AM IST  ·  BSE ID: a3477bc4-530c-4906-a845-0edeceab77e4
View Original BSE Filing (PDF)
💡
In Simple Terms
OneSource will manufacture biosimilar drugs for another company, Formycon, using its facilities.
🤖 AI Summary
  • OneSource Specialty Pharma and Formycon AG announce strategic manufacturing partnership.
  • OneSource will provide integrated Drug Substance and Drug Product manufacturing.
  • Partnership focuses on biosimilars development and manufacturing.
  • Manufacturing to occur at OneSource's Bangalore facility.
🏢 How This Affects the Company
📈
Business Impact
This partnership establishes OneSource Specialty Pharma as a manufacturing partner for biosimilars, potentially expanding its client base and project pipeline within the specialty pharma sector.
💰
Financial Impact
The filing does not provide financial terms or revenue projections for this partnership, so no direct financial impact can be determined at this stage.
⚙️
Operational Impact
OneSource will leverage its existing biologics facility in Bangalore for integrated Drug Substance and Drug Product manufacturing, requiring coordination with Formycon's development teams.
⚠️
Risk Impact
This venture introduces operational dependencies on Formycon's development success and the demand for its biosimilars, but does not appear to increase financial or regulatory risks directly.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders.
👤
Who Is Affected
All shareholders are affected by the company's strategic expansion into biosimilar manufacturing.
🔍
Management Signal
Management is signalling a commitment to expanding capabilities in specialized pharmaceutical manufacturing.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Updates on specific biosimilar projects under the partnership.
Details on manufacturing capacity utilization at the Bangalore facility.
Future announcements on Formycon's development pipeline progress.
LOW RISK Partnership announced; specific financial terms and risks are not detailed.
💡 Investor Takeaway
OneSource Specialty Pharma enters a strategic manufacturing partnership with Formycon AG for biosimilars, utilizing its Bangalore facility for integrated DS and DP production.
⚖️ Strengths & Concerns

✅ Positives

  • Partnership leverages OneSource's established biologics facility in Bangalore.
  • Formycon AG is an independent biosimilar developer based in Munich, Germany.
📅 Company Track Record
This is one of the first public filings for OneSource Specialty Pharma Limited, indicating a recent establishment or public market debut.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What is the nature of the partnership between OneSource Specialty Pharma and Formycon AG?
OneSource Specialty Pharma and Formycon AG have announced a strategic manufacturing partnership for biosimilars.
What services will OneSource Specialty Pharma provide to Formycon AG?
OneSource will provide integrated Drug Substance (DS) and Drug Product (DP) manufacturing capabilities.
Where will the manufacturing take place for this partnership?
Manufacturing will occur at OneSource Specialty Pharma's state-of-the-art biologics' facility in Bangalore.
What type of products will be manufactured under this agreement?
The partnership focuses on the manufacturing of biosimilars.

Questions based on this BSE filing only. For information purposes.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.